Bukhari, Wajih
Khalilidehkordi, Elham
Mason, Deborah F.
Barnett, Michael H.
Taylor, Bruce V.
Fabis-Pedrini, Marzena
Kermode, Allan G.
Subramanian, Sankar
Waters, Patrick
Broadley, Simon A.
Bukhari, Wajih
Khalilidehkordi, Elham
Mason, Deborah F.
Barnett, Michael H.
Taylor, Bruce V.
Fabis-Pedrini, Marzena
Kermode, Allan G.
Subramanian, Sankar
Waters, Patrick
Broadley, Simon A.
Abernethy, David
Bhuta, Sandeep
Blum, Stefan
Boggild, Mike
Boundy, Karyn
Brew, Bruce J.
Brilot, Fabienne
Brownlee, Wallace J.
Bundell, Christine S.
Butzkueven, Helmut
Carroll, William M.
Chen, Celia
Clarke, Laura
Coulthard, Alan
Dale, Russell C.
Das, Chandi
Dear, Keith
Fulcher, David
Gillis, David
Hawke, Simon
Heard, Robert
Henderson, Andrew P. D.
Heshmat, Saman
Hodgkinson, Suzanne
Jimenez Sanchez, Sofia
Kilpatrick, Trevor J.
King, John
Kneebone, Chris
Kornberg, Andrew J.
Lechner-Scott, Jeannette
Lin, Ming-Wei
Lynch, Chistopher
Macdonell, Richard A. L.
Marriott, Mark P.
McCombe, Pamela A.
O’Gorman, Cullen
Parratt, John D. E.
Pender, Michael P.
Pereira, Jennifer
Pollard, John D.
Prain, Kerri M.
Ramanathan, Sudarshini
Reddell, Stephen W.
Shaw, Cameron
Silvestrini, Roger A.
Slee, Mark
Spies, Judith
Stankovich, James
Sutton, Ian
Vincent, Angela
Vucic, Steve
Walsh, Michael
Willoughby, Ernest
Wong, Richard C.
Woodhall, Mark
Yiu, Eppie M.
,
Funding for this research was provided by:
Multiple Sclerosis Research Australia (11-038)
Griffith University
Article History
Received: 29 March 2021
Revised: 6 June 2021
Accepted: 14 June 2021
First Online: 2 July 2021
Declarations
:
: The authors declare no conflicts of interest of significance relevant to this manuscript. MHB has received honoraria for participation in advisory boards and travel sponsorship from Novartis, BioCSL, Genzyme, and Biogen Idec. MBo has received travel sponsorship and honoraria from Sanofi-Genzyme, Teva, Novartis, Biogen Idec, and Roche. BJB has received honoraria as a board member for GlaxoSmithKline, Biogen Idec, ViiV Healthcare, and Merck Serono, has received speaker honoraria from ViiV Healthcare, Boehringer Ingelheim, Abbott, Abbvie, and Biogen Idec; has received travel sponsorship from Abbott and Viiv Healthcare, and has received research support funding from EI Lilly, GlaxoSmithKline, ViiV Healthcare, and Merck Serono. SAB has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Scherring, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Genzyme, has received speakers honoraria from Biogen-Idec and Genzyme, is an investigator in clinical trials sponsored by Biogen Idec, Novartis, and Genzyme, and was the recipient of an unencumbered research grant from Biogen-Idec. HB has received honoraria for serving on scientific advisory boards for Biogen Idec, Novartis, and Sanofi-Genzyme, has received conference travel sponsorship from Novartis and Biogen Idec, has received honoraria for speaking and acting as Chair at educational events organised by Novartis, Biogen Idec, Medscape, and Merck Serono, serves on steering committees for trials conducted by Biogen Idec and Novartis, is chair (honorary) of the MSBase Foundation, which has received research support from Merck Serono, Novartis, Biogen Idec, Genzyme Sanofi, and CSL Biopharma, and has received research support form Merck Serono. WMC has been the recipient of travel sponsorship from, and provided advice to, Bayer Schering Pharma, Biogen-Idec, Novartis, Genzyme, Sanofi-Aventis, BioCSL and Merck-Serono. RCD has received research funding from the National Health and Medical Research Council, MS Research Australia, Star Scientific Foundation, Pfizer Neuroscience, Tourette Syndrome Association, University of Sydney, and the Petre Foundation and has received honoraria from Biogen-Idec and Bristol-Myers Squibb as an invited speaker. MjF-P has received travel sponsorship from Biogen-Idec and Merck Serono. RH has received honoraria, educational support, and clinic funding from Novartis, Biogen Idec, Genzyme, and BioCSL. AGK has received scientific consulting fees and/or lecture honoraria from Bayer, BioCSL, Biogen-Idec, Genzyme, Merck, Novartis, Sanofi-Aventis, and Teva. TJK has received travel sponsorship from Novartis, BioCSL, Novartis, Merck Serono, and Biogen Idec, has received speaker honoraria from Biogen Idec, BioCSL, Merck Serono, Teva, Genzyme, and Novartis, has received research support from Biogen Idec, Genzyme, GlaxoSmithKline, Bayer-Schering, and Merck Serono, and has received scientific consulting fees from GlaxoSmithKline China, Biogen-Idec, and Novartis. JK has received remuneration for advisory board activities and presentations from Bayer Healthcare, Biogen Idec, BioCSL, Genzyme, and Novartis. CK has received travel support, honoraria, and advisory board payments from Biogen Idec, Bayer, Genzyme, Novartis, and Serono. JL-S has received unencumbered funding as well as honoraria for presentations and membership on advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, CSL, Genzyme, Merck Serono, Novartis Australia, and Teva. RALM has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Scherring, Biogen-Idec, CSL, Merck-Serono, Novartis, and Sanofi-Genzyme. MPMa has received travel sponsorship, honoraria, trial payments, research, and clinical support from Bayer Schering, Biogen Idec, BioCSL, Genzyme, Novartis, and Sanofi Aventis Genzyme. DFM has received honoraria for attendance at advisory boards from Biogen-Idec and Novartis, and travel sponsorship from Bayer-Scherring, Biogen-Idec, and Sanofi-Genzyme. PAMcC has received honoraria or travel sponsorship from Novatis, Sanofi-Avnetis, and Biogen Idec. JAP has received travel sponsorship, honoraria for presentations, and membership on advisory boards from Biogen Idec and Novartis and Sanofi Aventis. JDP has received honoraria for seminars or advisory boards from Teva, Biogen, Sanofi-Genzyme, Novartis, Merck, Bayer and research grants or fellowships from Merck, Novartis, Bayer, Biogen, Sanofi-Genzyme and Teva. SWR has received travel sponsorship, honoraria, trial payments, research and clinical support from Aspreva, Baxter, Bayer Schering, Biogen Idec, BioCSL, Genzyme, Novartis, Sanofi Aventis Genzyme, and Servier, and is a director of Medical Safety Systems Pty Ltd. CPS has received travel sponsorship from Biogen Idec, Novartis, and Bayer-Schering. IS has received remuneration for Advisory Board activities from Biogen, CSL, and Bayer Schering and educational activities with Biogen, CSL and travel sponsorship from Biogen, Novartis, and Bayer Schering. MS has received research support from Novartis, Biogen Idec, and BioCSL. JSp has received honoraria for lectures and participation in advisory boards, and travel sponsorship from Novartis, BioCSL, Genzyme, and Biogen Idec. BVT has received travel sponsorship from Novartis and Bayer Schering. AV and the University of Oxford hold patents and receive royalties for antibody testing. PW and the University of Oxford hold patents for antibody assays and have received royalties, and have received speaker honoraria from Biogen Idec and Euroimmun® AG, and travel grants from the Guthy-Jackson Charitable Foundation. EW has received honoraria for participation in advisory boards from Biogen-Idec and Novartis, travel sponsorship from Biogen-Idec, Bayer-Schering, and Teva, and is an investigator in clinical trials funded by Biogen-Idec and Teva. MPP has received consulting fees and research funding from Atara Biotherapeutics. DA, SBh, SBl, KB, WBr, WBu, CSB, CCM, LC, AC, CD, KD, DF, DG, SHa, APDH, SHe, SHo, SJ-S, SS, AJK, M-WL, CL, CO’G, MPM, CS, RS, JSt, AV, SV, MWa, RCW, MWo, and EMY report no disclosures.